Net profit down up to 1765%! In the first half of the year, 70% of Chinese medicine enterprises registered negative growth.

Some time ago, the pharmaceutical manufacturing industry 2020 mid-year report has been basically disclosed, the impact of the epidemic has been basically minimized, production and sales are also basically restored, with rigid demand for the pharmaceutical industry ushered in a rebound, including biological products and innovative drugs and other high-boom areas to achieve rapid recovery, but the situation in the Chinese medicine industry is the opposite, the industry situation is not optimistic!According to stock research institutions such as Xiangcai Securities Research Institute, in the first half of the year: "The operating income of listed companies in the pharmaceutical industry increased by 3.3% YoY;
of listed companies in the Chinese medicine industry decreased by 12.89 percent year-on-year, total profit decreased by 30.30 percent year-on-year and net profit decreased by 30.42 percent year-on-year.
the pharmaceutical industry's overall performance is better, nearly 70% of the Chinese medicine industry's corporate income and non-profit margin growth showed a year-on-year decline, the situation is not optimistic.
70% of The decline in revenue of Chinese medicine companies is specifically from 67 Chinese pharmaceutical companies, total revenue in the first half of 2020 was 144.7 billion yuan, down 10% YoY, and net profit attributable to parents was 13.6 billion yuan, down 26% YoY.
According to the data, according to the industry classification, 67 Chinese medicine classification enterprises, only 18 enterprises operating income increased year-on-year, accounting for 26.9%, to Ling Pharmaceuticals due to the new crown pneumonia epidemic drug use, the first half of the revenue growth was significant, reaching 50.35 percent, ranking first in the industry.
followed by: Xiang Xue Pharmaceuticals, Red Day Pharmaceuticals, Huahua Pharmaceuticals, etc. , the increase in income is also obvious.
net profit, 45 pharmaceutical listed enterprises achieved negative growth, accounting for 67.16 percent, that is, nearly 70 percent of Chinese medicine enterprises in the first half of the year do not go back, industry pressure increased sharply; Ji Pharmaceutical Holdings, Zixin Pharmaceuticals, Yan Shenfa and Longjin Pharmaceuticals increased by -513.4%, -469.23%, -231.05% and -219.88%, respectively, making them the four largest declining enterprises in the first half of the year.
well-known Chinese medicine enterprises in the united States fell significantly.
Baiyunshan shares, for example, operating income in Baiyunshan fell 8.61 percent in the first half of 2020 from a year earlier, while net profit attributable to shareholders of listed companies fell 30.75 percent from a year earlier.
's operating income in the first half of 2020 decreased by 18.62 percent year-on-year, while net profit attributable to shareholders of listed companies decreased by 38.41 percent year-on-year.
In analyzing the reasons for the loss, Baiyunshan's semi-annual report said that due to the outbreak of new coronavirus pneumonia (the "new crown outbreak"), the company's products market demand decreased, sales revenue fell, production costs increased, resulting in a decrease in profits.
But the market consumption caused by the new crown epidemic, the global economic downturn is aimed at all industries, most industries in the pharmaceutical manufacturing industry have been affected, but the chemical medicine, raw materials industry after the stabilization of the recovery rate is significantly higher than Chinese medicine, which may also indicate that the "epidemic" for Chinese medicine In terms of the industry, more may be the overall downward "fuse" research and development investment is generally low, the industry "innovation" is insufficient from the Chinese medicine enterprises reported that, although the Chinese medicine enterprises research and development investment increased, but compared with other categories in the medical industry is still limited, research and development investment is the lowest in the pharmaceutical manufacturing industry.
same time, relative to the transformation and innovation of chemical pharmaceutical companies, although Chinese medicine enterprises are under pressure from health insurance charges, on the one hand, product research and development is more difficult, on the other hand, perhaps innovative thinking is not really open is fundamental.
statistics, in the past two years, the research and development expenditure of Chinese medicine enterprises has been maintained at about 2.3%, while the research and development expenditure of chemical agent enterprises has been increasing year by year.
According to experts, compared with the research and development investment of tens of millions or even hundreds of millions of yuan of Western pharmaceutical enterprises, another reason for the low investment in research and development of Chinese medicine enterprises, perhaps also has its own unique development law: Chinese medicine is derived from classic prescriptions, the efficacy is accurate and after hundreds or even thousands of years of historical verification, there is no need to invest as much in innovative research and development as Western medicine.
, but also proved that the current Chinese medicine industry is still stuck in the level of thousands of years ago, the slow replacement of the industry at the same time, the situation of green and yellow do not catch up has become a "dead end."
the number of approved new drugs approved for listing in 2015-2019, it can be seen that the bottom position of the new drug industry listed in Chinese medicine is obvious.
industry as a whole, as many as 9,000 Chinese medicine species and nearly 60,000 Chinese medicine approval numbers, the role in the market is really limited.
market demand is more with strong clinical demand and significant market value of innovative varieties of Chinese medicine.
theory and cognition, for the Chinese medicine industry is equally important At present, the situation of insufficient inheritance and innovation seriously restricts the development of Chinese medicine.
and with the continuous reflection of most practitioners in recent years, the characteristic requirements of Chinese medicine have been further highlighted, in line with the theoretical framework of Chinese medicine cognition, become the inevitable requirements of new Chinese medicine.
addition, a look at this year's approved Chinese medicine research and development cycle, none is more than a decade.
this long research and development cycle not only restricts the creation of new Chinese medicine, but also requires changes in the Chinese medicine industry.
In the past, the "short and smooth" development model of new Chinese medicine products "bulk" is gone, the future development of new Chinese medicine products, the inevitable requirement is "deep cultivation", from the clinical needs, through detailed, credible Chinese medicine characteristics of clear research, to prove its drug value.
All in all, after a long period of confusion and groping, the direction of development and policy trends have been basically clear, the path varies from person to person or different, but if you want to really mean the revival of "Chinese medicine heritage", it is time to regroup and get back on the road!